Type I Gaucher disease following chemotherapy for light chain multiple myeloma.
Although plasma cell disorders, such as hypergammaglobulinemia and monoclonal gammopathy of undetermined significance (MGUS), are reported to occur at higher incidences in patients with Type I Gaucher disease (GD) than in the normal population, pure light chain multiple myeloma (LCMM) has never been described in this context. Our case is the first to highlight a patient with LCMM who developed clinically apparent GD only following chemotherapy and hematopoietic stem cell transplantation. Renal complications are also exceedingly rare in GD, but nephrotic syndrome is one of the presenting features in this patient. The findings from this case will have important screening and diagnostic implications for both clinicians and patients.
Department of Internal Medicine, University of Manitoba, Winnipeg, Canada. wcheung.ca@gmail.com
Winson Y
WY
Cheung
Cheryl R
CR
Greenberg
Keevin
K
Bernstein
Brent
B
Schacter
Thomas
T
Fourie
Matthew D
MD
Seftel
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005776:Gaucher Disease / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000601:surgery; D009404:Nephrotic Syndrome / Q000175:diagnosis / Q000209:etiology
D000970:Antineoplastic Agents